Abiomed's Impella(R) Technology Showcased at ACC 2013

Abiomed's Impella(R) Technology Showcased at ACC 2013

DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD),
a leading provider of breakthrough heart support technologies, notes that
there will be over 15 Impella presentations in the scientific sessions at the
annual American College of Cardiology (ACC) 2013 scientific meeting, scheduled
from March 9 - 11, at the Moscone Convention Center in San Francisco.

On the ACC show floor, Abiomed will conduct daily booth demonstrations at
Abiomed booth #N6 - 233 and hands-on simulations of the Impella platform.

For further information about the ACC program related to Impella and the
timing of scientific presentations, please contact Aimee Genzler, Corporate
Communications Manager, at agenzler@abiomed.com or 978-646-1553.


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support. Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com.

The Abiomed logo is available at


This Release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including anticipated future losses, complex
manufacturing, high quality requirements, dependence on limited sources of
supply, competition, technological change, government regulation, future
capital needs and uncertainty of additional financing, and other risks and
challenges detailed in the Company's filings with the Securities and Exchange
Commission, including the Annual Report filed on Form 10-K and most recently
filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue
reliance on any forward-looking statements, which speak only as of the date of
this Release. The Company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements that may be made
to reflect events or circumstances that occur after the date of this Release
or to reflect the occurrence of unanticipated events.

CONTACT: For further information please contact:
         Aimee Genzler
         Corporate Communications Manager
         Susie Lisa
         Senior Director, Investor Relations, Corporate Development

Abiomed Logo
Press spacebar to pause and continue. Press esc to stop.